Heparin inhibits protective effect of ischemic preconditioning in ischemia/reperfusion-induced acute pancreatitis

Journal of Physiology and Pharmacology

Volumn 63, Issue 4, 2012, Pages 355-365

  Warzecha, Z ^a   Dembinski, A ^a   Ceranowicz, P ^a   Dembinski, M ^a   Sendur, R ^a   Cieszkowski, J ^a   Sendur, P ^a   Tomaszewska, R ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Acute pancreatitis; Coagulation; D dimer; Heparin; Ischemic preconditioning

Indexed keywords

AMYLASE; D DIMER; HEPARIN; HEPARINUM; INTERLEUKIN 10; INTERLEUKIN 1BETA; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; AMYLASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CLAMP; ARTICLE; CELIAC ARTERY; CONTROLLED STUDY; DISEASE SEVERITY; DNA SYNTHESIS; DRUG EFFECT; EDEMA; ENZYME ACTIVITY; HISTOPATHOLOGY; ISCHEMIC PRECONDITIONING; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; PANCREAS BLOOD FLOW; PANCREAS HEMORRHAGE; PANCREAS NECROSIS; PARTIAL THROMBOPLASTIN TIME; PROTECTION; RAT; REPERFUSION INJURY; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ANIMALS; ANTICOAGULANTS; HEPARIN; ISCHEMIC PRECONDITIONING; MALE; PANCREATITIS; RATS; RATS, WISTAR; REPERFUSION INJURY;

EID: 84867768847     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-1136
2. Kato H, Liu Y, Kogure K, Kato K. Induction of 27-kDa heat shock protein following cerebral ischemia in a rat model of ischemic tolerance. Brain Res 1994; 634: 235-244.
3. Turman MA, Bates CM. Susceptibility of human proximal tubular cells to hypoxia: effect of hypoxic preconditioning and comparison to glomerular cells. Ren Fail 1997; 19: 47-60
4. Kume, M, Yamamoto Y, Saad S, et al. Ischemic preconditioning of the liver in rats: implications of heat shock protein induction to increase tolerance of ischemiareperfusion injury. J Lab Clin Med 1996; 128: 251-258
5. Mounsey RA, Pang CY, Boyd JB, Forrest C. Augmentation of skeletal muscle survival in the latissimus dorsi porcine model using acute ischemic preconditioning. J Otolaryngol 1992; 21: 315-320
6. Pajdo R, Brzozowski T, Konturek PC, et al. Ischemic preconditioning, the most effective gastroprotective intervention: involvement of prostaglandins, nitric oxide, adenosine and sensory nerves. Eur J Pharmacol 2001; 427: 263-276
7. Dembinski A, Warzecha Z, Ceranowicz P, et al. Ischemic preconditioning reduces the severity of ischemia/reperfusioninduced pancreatitis. Eur J Pharmacol 2003; 473: 207-216
8. Warzecha Z, Dembinski A, Ceranowicz P, et al. Ischemic preconditioning inhibits development of edematous caerulein-induced pancreatitis: Involvement of cyclooxygenases and heat shock protein 70. World J Gastroenterol 2005; 11: 5958-5965
9. Dembinski A, Warzecha Z, Ceranowicz P, et al. Effect of ischemic preconditioning on pancreatic regeneration and pancreatic expression of vascular endothelial growth factor and platelet-derived growth factor-A in ischemia/reperfusion-induced pancreatitis. J Physiol Pharmacol 2006; 57: 39-58
10. Warzecha Z, Dembinski A, Ceranowicz P, et al. Influence of ischemic preconditioning on blood coagulation, fibrinolytic activity and pancreatic repair the course of caeruleininduced acute pancreatitis in rats. J Physiol Pharmacol 2007; 58: 303-319
11. Hogan AR, Doni M, Ribeiro MM, et al. Ischemic preconditioning improves islet recovery after pancreas cold preservation. Transplant Proc 2009; 41: 354-355
12. Perretti M, Page CP. Heparin and inflammation: a new use for an old GAG? Gut 2000; 47: 14-15
13. Gaffney A, Gaffney P. Rheumatoid arthritis and heparin. Br J Rheumatol 1996; 35: 808-809
14. Bowler SD, Smith SM, Lavercombe PS. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis 1993; 147: 160-163
15. Dwarakanath AD, Yu LG, Brookers C, Pryce D, Rhodes JM. 'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut 1995; 37: 585-588
16. Warzecha Z, Dembinski M, Ceranowicz P, Dembinski A. Heparyna i jej dzialanie przeciwzapalne w ukladzie pokarmowym (Heparin and its anti-inflammatory action in the gut). Gastroenterol Pol 2010; 17: 227-233.
17. Salas A, Sans M, Soriano A, et al. Heparin attenuates TNFalpha induced inflammatory response through a CD11b dependent mechanism. Gut 2000; 47: 88-96
18. Lever R, Lo WT, Faraidoun M, et al. Size-fractionated heparins have differential effects on human neutrophil function in vitro. Br J Pharmacol 2007; 151: 837-843
19. Hornebeck W, Lafuma C, Robert L, Moczar M, Moczar E. Heparin and its derivatives modulate serine proteinases (SERPS) serine proteinase inhibitors (SERPINS) balance. Physiopathological relevance. Pathol Res Pract 1994; 190: 895-902.
20. Sissi C, Lucatello L, Naggi A, Torri G, Palumbo M. Interactions of low-molecular-weight semi-synthetic sulfated heparins with human leukocyte elastase and human cathepsin G. Biochem Pharmacol 2006; 71: 287-2893.
21. Ewangelista V, Piccardoni P, Maugeri N, De Gaetano G, Cerletti C. Inhibition by heparin of platelet activation induced by neutrophil-derived cathepsin G. Eur J Pharmacol 1992; 216: 401-405.
22. Gabryelewicz A, Niewiarowski S, Prokopowicz J, Chlebowski J. Heparin and protease inhibitors in the prevention of experimental acute pancreatic necrosis in dogs. Digestion 1969; 2: 7-16.
23. Qiu F, Lu XS, Huang YK. Effect of low molecular weight heparin on pancreatic micro-circulation in severe acute pancreatitis in a rodent model. Chin Med J 2007; 120: 2260- 2263.
24. Dobosz M, Wajda Z, Hac S, et al. Heparin and nitric oxide treatment in experimental acute pancreatitis in rats. Forum (Genova)1998; 8: 303-310
25. Ceranowicz P, Dembinski A, Warzecha Z, et al. Protective and therapeutic effect of heparin in acute pancreatitis. J Physiol Pharmacol 2008; 59(Suppl. 4): 103-125
26. Ceranowicz P, Dembinski M, Warzecha Z, et al. Healing effect of heparin in the course of edematous, ceruleininduced acute pancreatitis. Przeglad Gastroenterol 2009; 4: 199-205
27. Rabenstein T, Roggenbuck S, Framke B, et al. Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP? Gastrointest Endosc 2002; 55: 476-483
28. Alagozlu H, Cindoruk M, Karakan T, Unal S. Heparin and insulin in the treatment of hypertriglyceridemia-induced severe acute pancreatitis. Dig Dis Sci 2006; 51: 931-933
29. Kyriakidis AV, Raitsiou B, Sakagianni A, et al. Management of acute severe hyperlipidemic pancreatitis. Digestion 2006; 73: 259-264
30. Jain P, Rai RR, Udawat H, Nijhawan S, Mathur A. Insulin and heparin in treatment of hypertriglyceridemia-induced pancreatitis. World J Gastroenterol 2007; 13: 2642-2643
31. Lu XS, Qiu F, Li YX, Li JQ, Fan QQ, Zhou RG. Effect of lower-molecular weight heparin in the prevention of pancreatic encephalopathy in the patient with severe acute pancreatitis. Pancreas 2010; 39: 516-519
32. Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 2006; 96: 547-552
33. Dembinski A, Warzecha Z, Ceranowicz P, et al. Pancreatic damage and regeneration in the course of ischemia-induced acute pancreatitis in rats. J Physiol Pharmacol 2001; 52: 221-236
34. Konturek SJ, Szlachcic A, Dembinski A, Warzecha Z, Jaworek J, Stachura J. Nitric oxide in pancreatic secretion and hormone-induced pancreatitis in rats. Int J Pancreatol 1994; 15: 19-28
35. Warzecha Z, Ceranowicz P, Dembinski A, et al. Therapeutic effect of ghrelin in the course of ceruleininduced acute pancreatitis in rats. J Physiol Pharmacol 2010; 61: 419-427
36. Ceranowicz D, Warzecha Z, Dembinski A, et al. Role of hormonal axis, growth hormone - IGF-1, in the therapeutic effect of ghrelin in the course of cerulein-induced acute pancreatitis. J Physiol Pharmacol 2010; 61: 599-606
37. Dembinski A, Jaworek J, Konturek PK, Konturek SJ, Warzecha Z. Cholecystokinin receptor antagonism by peptidergic and non-peptidergic agents in rat pancreas. J Physiol 1989; 411: 419-435
38. Tomaszewska R, Dembinski A, Warzecha Z, Ceranowicz P. Morphological changes and morphological-functional correlations in acute experimental ischemia/reperfusion pancreatitis in rats. Pol J Pathol 2000; 51: 179-184
39. Murry CE, Richard VJ, Reimer KA, Jennings RB. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res 1990; 66: 913-931
40. Li YJ, Xiao ZS, Peng CF, Deng HW. Calcitonin gene-related peptide-induced preconditioning protects against ischemiareperfusion injury in isolated rat hearts. Eur J Pharmacol 1996; 311: 163-167.
41. Fryer RM, Auchampach JA, Gross GJ. Therapeutic receptor targets of ischemic preconditioning. Cardiovasc Res 2002; 55; 520-525
42. Ucar G, Topaloglu E, Burak Kandilci H, Gumusel B. Elevated semicarbazide-sensitive amine oxidase (SSAO) activity in lung with ischemia-reperfusion injury: protective effect of ischemic preconditioning plus SSAO inhibition. Life Sci 2005; 78: 421-427
43. Williams-Pritchard G, Knight M, Hoe LS, Headrick JP, Peart JN. Essential role of EGFR in cardioprotection and signaling responses to A1 adenosine receptors and ischemic preconditioning. Am J Physiol Heart Circ Physiol 2011; 300: H2161-H2168
44. Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989; 58: 575-606
45. Ashikari-Hada S, Habuchi H, Kariya Y, Itoh N, Reddi AH, Kimata K. Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. J Biol Chem. 2004; 279: 12346-12354
46. Gitay-Goren H, Soker S, Vlodavski I, Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem 1992; 267: 6093-6098
47. Muramatsu T, Muramatsu H. Glycosaminoglycan-binding cytokines as tumor markers. Proteomics 2008; 8: 3350-3359
48. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991; 251: 936-939
49. Thompson SA, Higashiyama S, Wood K, et al. Characterization of sequences within heparin-binding EGFlike growth factor that mediate interaction with heparin. J Biol Chem 1994; 269: 2541-2549
50. Gitay-Goren H, Soker S, Vlodavski I, Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem 1992; 267: 6093-6098
51. Rapraeger AC, Krufka A, Olwin BB. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 1991; 252: 1705-1708
52. Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 1993; 259: 1918-1921
53. Saksela O, Moscatelli D, Sommer A, Rifkin DB. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 1988; 107: 743-751
54. Menke A, Yamaguchi H, Giehl K, Adler G. Hepatocyte growth factor and fibroblast growth factor 2 are overexpressed after cerulein-induced acute pancreatitis. Pancreas 1999; 18: 28-33
55. Konturek PC, Dembinski A, Warzecha Z, et al. Comparison of epidermal growth factor and transforming growth factorbeta1 expression in hormone-induced acute pancreatitis in rats. Digestion 1998; 59: 110-119
56. Ebert M, Yokoyama M, Ishiwata T, et al. Alteration of fibroblast growth factor and receptor expression after acute pancreatitis in humans. Pancreas 1999; 18: 240-246
57. Warzecha Z, Dembinski A, Konturek PC, Ceranowicz P, Konturek SJ. Epidermal growth factor protects against pancreatic damage in cerulein-induced pancreatitis. Digestion 1999; 60: 314-323
58. Dembinski A, Warzecha Z, Konturek PC, et al. Epidermal growth factor accelerates pancreatic recovery after caerulein-induced pancreatitis. Eur J Pharmacol 2000; 398: 159-168
59. Hosokawa M, Tsukada H, Fukuda F, et al. Therapeutic effect of basic fibroblast growth factor on experimental pancreatitis in rat. Pancreas 2000; 20: 373-377
60. Warzecha Z, Dembinski A, Konturek PC, et al. Hepatocyte growth factor attenuates pancreatic damage in caeruleininduced pancreatitis in rats. Eur J Pharmacol 2001; 430: 113-121
61. Warzecha Z, Dembinski A, Ceranowicz P, et al. IGF-1 stimulates production of interleukin-10 and inhibits development of caerulein-induced pancreatitis. J Physiol Pharmacol 2003; 54: 575-590
62. Jaworek J, Leja-Szpak A, Dembinski A, et al. Involvement of sensory nerves in the protective effect of growth hormone on acute pancreatitis. Growth Horm IGF Res 2009; 19: 517-522
63. Dembinski A, Warzecha Z, Ceranowicz P, et al. Role of growth hormone and insulin-like growth factor-1 in the protective effect of ghrelin in ischemia/reperfusion-induced acute pancreatitis. Growth Horm IGF Res 2006; 16: 348- 356
64. Warzecha Z, Dembinski A. Protective and therapeutic effects of ghrelin in the gut. Curr Med Chem 2012; 19: 118-125
65. Kuhn MA, Xia G, Mehta VB, Glenn S, Michalsky MP, Besner GE. Heparin-binding EGF-like growth factor (HBEGF) decreases oxygen free radical production in vitro and in vivo. Antioxid Redox Signal 2002; 4: 639-646
66. El-Assal ON, Besner GE. Heparin-binding epidermal growth factor-like growth factor and intestinal ischemiareperfusion injury. Semin Pediatr Surg 2004; 13: 2-10
67. Zhang HY, James I, Chen CL, Besner GE. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) preserves gut barrier function by blocking neutrophilendothelial cell adhesion after hemorrhagic shock and resuscitation in mice. Surgery 2012; 151: 594-605
68. Radulescu A, Yu X, Orvets ND, Chen Y, Zhang HY, Besner GE. Deletion of the heparin-binding epidermal growth factor-like growth factor gene increases susceptibility to necrotizing enterocolitis. J Pediatr Surg 2010; 45: 729-734
69. Teoh N, Leclercq I, Pena AD, Farrell G. Low-dose TNFalpha protects against hepatic ischemia-reperfusion injury in mice: implications for preconditioning. Hepatology 2003; 37: 118-128
70. Jaworek J, Jachimczak B, Tomaszewska R, et al. Protective action of lipopolysaccharides in rat caerulein-induced pancreatitis: role of nitric oxide. Digestion 2000; 62: 1-13
71. Dembinski A, Warzecha Z, Konturek SJ, et al. Extract of grapefruit-seed reduces acute pancreatitis induced by ischemia/reperfusion in rats: possible implication of tissue antioxidants. J Physiol Pharmacol 2004; 55: 811-821
72. Warzecha Z, Dembinski A, Jaworek J, et al. Role of sensory nerves in pancreatic secretion and caerulein-induced pancreatitis. J Physiol Pharmacol 1997; 48: 43-58
73. Tripodi A, Mannucci PM. Markers of activated coagulation and their usefulness in the clinical laboratory. Clin Chem 1996; 42: 664-669
74. Campbell DJ. The kallikrein-kinin system in humans Clin Exp Pharmacol Physiol 2001; 28: 1060-1065
75. White M. Mediators of inflammation and the inflammatory process. J Allergy Clin Immunol 1999; 103: S378-S381.
76. Goto M, Liu Y, Yang XM, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 1995; 77: 611-621
77. Griol-Charhbili V, Messadi-Laribi E, Bascands JL, et al. Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J 2005; 19: 1172-1174
78. Gozzo AJ, Motta G, Cruz-Silva I, et al. Heparin affects the interaction of kininogen on endothelial cells. Biochimie 2011; 93: 1839-1845
79. Oschatz C, Maas C, Lecher B, et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 2011; 34: 258-268
80. Clavien PA, Yadav S, Sindram D, Bentley RC. Protective effects of ischemic preconditioning for liver resection performed under inflow occlusion in humans. Ann Surg 2000; 232: 155-162
81. Petrowsky H, Mc Cormak L, Trujillo M, Selzner M, Jochum W, Clavien PA. A prospective, randomized, controlled trial comparing intermittent portal triad clamping versus ischemic preconditioning with continuous clamping for major liver resection. Ann Surg 2006; 244: 921-928.
82. Holscher AH, Schneider PM, Gutschow C, Schroder W. Laparoscopic ischemic conditioning of the stomach for esophageal replacement. Ann Surg 2007; 245: 241-246
83. Cheung MM, Kharbanda RK, Konstantinov IE, et al.Randomized controlled trial of the effects of remote ischemic preconditioning on children undergoing cardiac surgery: first clinical application in humans. J Am Coll Cardiol 2006; 47: 2277-2282
84. Hausenloy DJ, Mwamure PK, Venugopal V, et al. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet 2007; 370(9587): 575-579
85. Chan MT, Boet R, NG SC, Poon WS, Gin T. Effect of ischemic preconditioning on brain tissue gases and pH during temporary cerebral artery occlusion. Acta Neurochir 2005; 95(Suppl): 93-96.